Punarnava (Boerhavia diffusa L.): A Comprehensive Reference
1. Identity: Botanical Classification, Nomenclature, and Natural Sources
Taxonomy and Botanical Description
Boerhavia diffusa L. (synonym: Boerhaavia diffusa L.) — the plant most commonly sold and studied under the name punarnava — is a perennial, spreading herb belonging to the family Nyctaginaceae. The genus Boerhaavia L. encompasses approximately 40 tropical and subtropical species found growing wild in different terrestrial habitats, ranging from managed grasslands and wastelands to agro-ecosystems and large forest gaps. Plants of this genus grow vigorously as weeds in tropical and subtropical regions including India, Brazil, Africa, Australia, China, Egypt, Pakistan, Sudan, Sri Lanka, the USA, Iran, and several countries of the Middle East.
Boerhavia diffusa is a perennial herb with a stout rootstock and many procumbent branches, bearing pale rose-coloured, small, short-stalked flowers; its fruits are highly viscid and one-seeded. The plant is known by many vernacular names in India, including Punarnava, Raktapunarnava, Shothaghni, Kathillaka, Kshudra, Varshabhu, Raktapushpa, Varshaketu, and Shilatika.
The genus name Boerhaavia was assigned to honour Hermann Boerhaave, a famous 18th-century Dutch physician, and the species is named diffusa due to its characteristic spreading growth habit. Six species of Boerhaavia are reported to occur in India: B. diffusa, B. chinensis, B. erecta, B. repens, B. rependa, and B. rubicunda.
The Name "Punarnava"
Popularly called Punarnava, the name means "renewer" or "rejuvenator of the body" because of its anti-aging property. It is understood to rejuvenate the whole body, enhancing vigour and vitality upon routine use — a meaning that directly justifies its Indian name Punarnava.
Plant Parts Used and Common Preparations
The roots are the source of a novel class of isoflavonoids known as rotenoids, flavonoids, flavonoid glycosides, xanthones, purine nucleoside, lignans, ecdysteroids, and steroids. Parts used traditionally include the root and the whole plant, occasionally the leaves.
Commercial and traditional preparations include:
- Dried root powder, which is typically mixed with warm water or honey and taken once or twice daily.
- Capsules and tablets containing standardized punarnava extract are widely available from Ayurvedic and herbal supplement companies. Liquid extracts and tinctures offer another option, and some people brew the dried root or leaves as a tea.
- In traditional Ayurvedic practice, the fresh juice of the whole plant is sometimes recommended, particularly for acute fluid retention.
- Ointment made with a paste of the roots of Punarnava — the root is made into a paste with ghee, honey, milk, Kanjika, or Tila Taila and used as an ointment for multiple purposes.
- In classical Ayurvedic formulations, punarnava appears in preparations such as Punarnavadi Kashayam (a decoction) and Punarnavadi Guggulu (a tablet preparation), often combined with other herbs to target specific conditions.
- Punarnavasava is a traditional asava (fermented herbal decoction) in Ayurveda, formulated primarily with the rejuvenative Punarnava root (Boerhaavia diffusa) alongside other synergistic botanicals.
The roots and leaves of B. diffusa represent substantial differences with respect to chemical constituents, and it has also been reported that the same plant part, whether leaves or roots, collected from different geographical origins may have different metabolite profiles.
2. Traditional and Historical Use
Ayurvedic Medicine (India)
Boerhavia diffusa L. is a medicinal plant of remarkable historical significance, deeply rooted in the traditional healthcare practices of the Indian subcontinent and other tropical regions. Its continuous use over centuries reflects the confidence of traditional physicians in its therapeutic value and highlights its enduring relevance in human health.
Classical treatises like the Charaka Samhita and Sushruta Samhita mention "Punarnava" under indications for Mutra-vidradhi (urinary tract disorders), dropsical swelling, and generalized debility. Known as Punarnava in Ayurveda, the plant is used in Asia and Africa as a rejuvenator or "Rasayan" for its excellent antiaging and antioxidant properties.
In Ayurveda, punarnava is recognized as a mutrala (diuretic) herb that helps support urination and fluid balance. It features in classical preparations for urinary comfort, water retention, and rejuvenation (rasayana).
It has emetic, expectorant, diaphoretic, stomachic, laxative, and diuretic properties. Due to its multifarious therapeutic potential against abdominal pain, diarrhoea, epilepsy, dysentery, urinary and kidney complications, jaundice, anaemia, pneumonia, and splenomegaly, it is extensively used globally as a rejuvenator in various medicinal formulations, especially in Asia, Africa, and Latin America.
Boerhaavia diffusa is well documented as a diuretic and is also used in the treatment of anaemia, scanty urine, and ascites. Various parts of the plant are used in many different infirmities such as rheumatism, hepatitis, urinary disorders, asthma, internal inflammation disorders, blood pressure, leucorrhoea, as an expectorant and emetic, and as an analgesic and anti-inflammatory.
Classical Formulations and Their Origins
Punarnavasava's earliest recorded mention is found in the Ashtanga Hridaya (Chikitsa Sthana), attributed to Acharya Vagbhata around the 7th century CE.
Known as Punarnava in Ayurveda, it is a main ingredient in many Ayurvedic formulations. It is used as traditional medicine by indigenous people of many countries for its protective role against inflammation, prostatic hyperplasia, diabetes, cancer, gastrointestinal problems, arthritis, and more.
Use Across Traditions and Regions
It is used in Ayurveda in Asia and Africa as a rejuvenator or "Rasayan" for its excellent antiaging and antioxidant properties.
In Bengali medicine, punarnava is highly regarded for its diuretic and anti-inflammatory properties, making it effective for managing conditions like kidney issues, swelling, and liver disorders. Traditional uses in Bengal include utilizing its roots and leaves, often in the form of herbal preparations such as teas or decoctions to promote kidney function and reduce water retention.
The plant is widely used as a green leafy vegetable as well as an important indigenous medicinal plant with many biological properties. Punarnava is typically consumed as a herbal tea or powder, and sometimes even cooked with food, especially in soups or stews for its health benefits.
3. Key Constituents and Active Compounds
Overview of Phytochemical Classes
The phytochemical makeup of Boerhavia diffusa comprises alkaloids, flavonoids, glycosides, phenolics, and saponins, all of which contribute to its various pharmacological properties. More specifically, the most comprehensively characterized compound classes include:
- Phenolics: The most widely reported phenolic compounds are punarnavoside, trans-caftaric acid, and boerhavic acid.
- Rotenoids (Boeravinones): The roots of B. diffusa have yielded numerous isolated rotenoids. Among its constituents is a group of compounds termed boeravinones, including boeravinone A, B, C, D, E, and F. Examination of the ether extracts of the roots has led to the isolation of boeravinone A, B, C, D, E, F, G, and H.
- Alkaloids: Two quinolizidine alkaloids identified as punarnavine-I and punarnavine-II were isolated from the root, stem, and leaves. The distribution of these alkaloids was maximum in the stem and minimum in the root.
- Flavonoids: The flavonoid constituents include borhaavone, quercetin, and kaempferol. Roots also presented flavonoid derivatives quercetin-3-O-robinobioside and eupalitin-3-O-galactosyl (1-2)-glucoside, as well as one phenolic acid, caffeoyltartaric acid, which was absent in leaves.
- Isoflavonoids: Isoflavonoid constituents include 2′-O-methyl abronisoflavone.
- Steroids and ecdysteroids: Steroid constituents include boerhavisterol and β-Ecdysone. A phytoecdysone named ecdysterone, which acts as an insect moulting hormone, was also isolated from the root extracts.
- Lignans: Two known lignans, liriodendrin and syringaresinol mono-β-D-glycoside, have been isolated.
- Other compounds: Additional classes include steroids, triterpenoids, lipids, carbohydrates, proteins, and glycoproteins from leaves, stems, seeds, and roots.
Spasmolytic Rotenoids
A bioassay-guided separation of a methanolic extract obtained from the roots of B. diffusa L. allowed the isolation of five compounds belonging to the class of rotenoids, out of which three were known compounds (boeravinone D, boeravinone E, and a rotenoid 5) along with two novel compounds (boeravinone G and boeravinone H). Boeravinone G, boeravinone E, and rotenoid 5 exhibited spasmolytic activity.
Key Mechanisms of Action
The immunosuppressive activity of B. diffusa extract and its active ingredient luteolin has been investigated at the molecular level. It was found that B. diffusa extract markedly suppressed the activation of NF-κB by blocking a series of signalling cascades ranging from Syk/Src to IκBα.
The diuretic activity of the plant is attributed to increased sodium excretion rate, which is due to the presence of various phytochemicals including glucosides and ecdysone from various parts of the plant.
B. diffusa contains a large number of compounds such as flavonoids, alkaloids (punarnavine), steroids, triterpenoids, lipids, lignins, carbohydrates, proteins, and glycoproteins. Flavonoids, alkaloids, glycosides, and sterols have established antioxidant activity.
In the context of tacrolimus-induced nephrotoxicity studied in MDCK cell lines, co-treatment with an ethyl acetate fraction of B. diffusa decreased collagen accumulation with a significant increase in cell survival of tubular epithelial cells. HPLC analysis showed the presence of quercetin (87.5 mg/g) in the ethyl acetate fraction, which may be responsible for the nephroprotective role.
Punarnavine has been reported to possess powerful diuretic activity.
4. Scientific Evidence by Area of Use
4.1 Renal and Urinary System (Nephroprotective and Diuretic Effects)
Summary of evidence strength: Preclinical (animal and in vitro) evidence is substantial; genuine human clinical evidence remains very limited.
The scientific literature covers administration of B. diffusa for acute kidney injury, chronic kidney disease, polycystic kidney disease, renal calculi, urinary tract infection, and COVID-19-related kidney disease. The nephroprotective effect of B. diffusa has been demonstrated in in vitro, in vivo, and in clinical studies.
Irrespective of the type of B. diffusa extract employed, animal studies showed reduction in the key markers of kidney diseases — urea, creatinine, BUN, and proteins. The plant also has an antifibrotic property, reducing the formation of extracellular collagen deposition in the renal tubules, though this has not been much explored.
In one preclinical study examining gentamicin-induced nephrotoxicity: the study was conducted in two parts using 40 rats in each part. Rats were equally divided into five groups. Group 1 served as normal control, Group 2 as disease control, and Groups 3, 4, and 5 received α-lipoic acid (ALA) and 200 and 400 mg/kg of B. diffusa, respectively. All groups except Group 1 concomitantly received gentamicin 150 mg/kg/day for 10 days. Parameters measured included blood urea nitrogen (BUN), serum creatinine, kidney malondialdehyde (MDA), and glutathione (GSH) levels, kidney injury on histopathology, and paraaminohippurate (PAH) clearance.
Clinical studies in humans have employed polyherbal combinations containing B. diffusa extract. Irrespective of the type of B. diffusa extract, all reviewed studies showed reduction in the key markers of kidney diseases — urea, creatinine, BUN, and proteins.
Reviewers highlight the importance of further research required in establishing the molecular mechanisms underlying the action of B. diffusa. With in-depth molecular research and clinical trials, B. diffusa could be developed into a novel therapeutic agent for the successful treatment of renal disorders, especially chronic kidney disease.
Studies have demonstrated the effect of B. diffusa extract on kidney function and diuretic conditions. The diuretic activity is also attributed to increased sodium excretion rate.
In vitro evidence in MDCK cell lines provides evidence that an ethyl acetate fraction of B. diffusa may be an effective adjuvant therapy to prevent nephrotoxicity induced by tacrolimus (TAC). This evidence remains in vitro and cannot currently be extrapolated to human clinical use without further study.
4.2 Hepatoprotective Activity
Summary of evidence strength: Predominantly animal and in vitro; no large, well-designed human trials identified in the reviewed literature.
B. diffusa has long been used as a popular hepatoprotective medicine. Evidence supports B. diffusa's hepatoprotective, nephroprotective, and immunomodulatory activities in various animal models.
In traditional formulations, punarnava often appears in blends promoting liver wellness. Animal and laboratory research has shown antioxidant and hepatoprotective (liver-protecting) potential, but robust human trials are lacking.
There is abundant evidence of B. diffusa being an important remedy in generalized edema and kidney-liver disorder due to its diuretic and hepatoprotective activities.
4.3 Anti-Inflammatory and Analgesic Activity
Summary of evidence strength: Mechanism work in vitro and animal models; no controlled human trials identified.
Boerhavia diffusa exhibits diverse pharmacological properties, including analgesic and anti-inflammatory effects. A 95% ethanol extract of B. diffusa has been shown to suppress inflammatory response both in vivo (mouse gastritis ulcer model) and in vitro (LPS-treated RAW264.7 cells) in a dose-dependent manner at 20 to 200 mg/kg body weight, a suppressive effect comparable to the standard drug ranitidine at 40 mg/kg body weight.
In a study evaluating the combination of Boerhaavia diffusa and Tinospora cordifolia against diclofenac-induced nephrotoxicity in rats, the herbal combination exhibited significant (p < 0.05) nephroprotective effect by reducing renal oxidative and inflammatory stress.
4.4 Antidiabetic Activity
Summary of evidence strength: Demonstrated in animal models with plausible mechanisms; no robust human clinical trials identified.
Research indicates B. diffusa has potential antidiabetic effects, with significant reductions in blood glucose levels in diabetic models. B. diffusa has been reported to lower blood glucose levels via increasing insulin release from pancreatic cells.
4.5 Cardioprotective Activity
Summary of evidence strength: Preclinical evidence only.
The plant is reported to possess cardiotonic and antihypertensive potential. Previous studies have shown the antihypertrophic potential of B. diffusa against angiotensin II-induced hypertrophy in H9c2 cells by downregulating oxidative stress along with its potent antioxidant capacity. Cardioprotective effects have been reported in preclinical settings, reinforcing traditional applications in chronic and lifestyle-related disorders.
4.6 Anticancer and Anti-Metastatic Activity
Summary of evidence strength: In vitro and animal model data only; no human clinical trials identified.
Whole plant of B. diffusa at 0.5 mg/dose has inhibited metastasis formation by B16F10 melanoma cells by approximately 95% in C57BL/6 mice. In an in vitro hormone-dependent human breast cancer model, the methanolic extract of the whole plant of B. diffusa showed a 46.8% reduction in cell viability in MCF-7 cells in 48 h at 320 µg/mL.
Punarnavine, an alkaloid from Boerhaavia diffusa, exhibits anti-angiogenic activity via downregulation of VEGF in vitro and in vivo.
4.7 Immunomodulatory Activity
Summary of evidence strength: Preclinical; the plant has shown both immunostimulatory and immunosuppressive properties depending on context and extract type.
Pharmacological studies have demonstrated that B. diffusa is known to possess anticonvulsant, diuretic, anti-inflammatory, antifibrinolytic, antibacterial, anti-hepatotoxic, anthelmintic, febrifuge, anti-leprosy, antiasthmatic, antiurethritis, antilymphoproliferative, antimetastatic, immunosuppressive, antidiabetic, antioxidant, immune-modulatory, hepatoprotective, anti-nociceptive, nephroprotective, and antiurolithiatic activities.
4.8 Antioxidant Activity
Summary of evidence strength: Well-documented in vitro; antioxidant capacity underpins many of the other proposed activities.
Methanol extract showed higher antioxidant and thrombolytic activity and less cytotoxic activity than the n-hexane and ethyl acetate extracts of B. diffusa. Among the bioactivities, antioxidant activity was the most notable compared to the positive control, suggesting it could be a potential rich source of natural antioxidants.
4.9 Wound Healing
Summary of evidence strength: Preliminary in vitro and animal model evidence.
B. diffusa possesses significant wound-healing potential, where D-pinitol and caffeic acid served as the lead constituent metabolites responsible for the healing.
4.10 Clinical Evaluation in Tuberculosis
A clinical evaluation of Boerhaavia diffusa as an adjuvant in the treatment of pulmonary tuberculosis was reported in the journal Phytomedica (2001). However, the specific clinical outcomes, patient numbers, and methodology from this study could not be fully retrieved in the sources available for this article, and no conclusions about efficacy should be drawn without access to the full publication.
5. Body Systems and Health Areas of Association
The crude extract and the isolated phytochemicals of B. diffusa are reported to have impressive bioactivities, including immunomodulatory, hepatoprotective, renoprotective, cardioprotective, antidiabetic, anti-inflammatory, antifertility, antioxidant, anticancer, and antimicrobial properties.
The following body systems are most prominently associated with punarnava in both the traditional and scientific literature:
- Urinary/Renal System: B. diffusa is one of the chief ingredients in Ayurvedic formulations used for urinary diseases.
- Hepatobiliary System: It has been used in the treatment of conditions such as hepatotoxicity and jaundice.
- Cardiovascular System: Boerhavia diffusa is mentioned in ethnopharmacological studies as a therapy for cardiovascular disorders.
- Immune System: Various animal studies and trials have confirmed the presence of immunomodulation and antifibrinolytic activities.
- Metabolic/Endocrine (Diabetes): Animal research has demonstrated antidiabetic effects through multiple mechanisms.
- Respiratory System: Some of the demonstrated or reported effects include anti-inflammatory and antiasthmatic properties, and less prominently, adaptogenic activity.
- Reproductive System: Research has investigated the antiimplantation and antiestrogenic activity of Boerhaavia diffusa root extract in female rats.
6. Dosage Forms and Dosages Reported in Studies
The dosage of punarnava varies considerably depending on the form and the practitioner's assessment. There is no universally agreed-upon standardized dose because large-scale clinical trials establishing optimal amounts have not been completed.
Specific dosages that have been used in identified studies (animal unless otherwise noted):
- In the rat nephrotoxicity model, test groups received 200 and 400 mg/kg of aqueous root extract of B. diffusa, with comparator groups receiving gentamicin 150 mg/kg/day for 10 days.
- In a mouse gastritis/ulcer model, 95% ethanol extract suppressed inflammatory response in a dose-dependent manner at 20 to 200 mg/kg body weight.
- In an experimental primate study, the 50% aqueous ethanolic extract of root, when administered orally in experimental monkeys, was found to stop IUCD-induced bleeding at 50 mg/kg body weight.
- An ethanolic extract of root at a dose of 250 mg/kg body weight daily, administered orally to pregnant albino female rats during the entire period of gestation, did not show any teratogenic effects; litter size and survival rate of foetuses were the same as the normal control group, and no foetal abnormality was detected.
- In a comparative clinical evaluation (in dogs, not humans), Boerhavia diffusa root extract was evaluated in canine chronic renal failure (CRF) in comparison with standard enalapril. A total of 20 dogs were divided into two groups (n = 10).
- The most commonly employed extracts across reviewed studies were aqueous, hydroalcoholic, ethanolic, and methanolic extracts.
The most commonly employed extract types across the nephroprotective literature were aqueous, hydroalcoholic, ethanolic, and methanolic extracts.
7. Safety Considerations and Interactions
General Tolerability
Punarnava is generally considered safe when used in traditional food amounts or standard supplemental doses. It has a long history of human consumption both as medicine and as a cooked green vegetable, which provides some reassurance about its basic safety.
Antifertility and Reproductive Concerns
Animal studies have raised antifertility signals that are relevant to human safety assessment. The present study was conducted to investigate the antiimplantation and antiestrogenic activity of Boerhaavia diffusa root extract in female rats; disturbance of the natural steroid hormone balance can disorganize coordinated events involved in ovulation, ovum transport, and implantation, and compounds possessing anti-estrogenic or anti-progestational activity may also exhibit anti-fertility activity. These data come from animal research and have not been confirmed in human trials, but they constitute a meaningful safety signal.
Immunosuppressive Properties
Pharmacological studies have demonstrated that B. diffusa possesses immunosuppressive activity. This property, while potentially useful in certain inflammatory contexts, raises a concern regarding use in individuals already on immunosuppressant medications. In vitro evidence suggests that a fraction of B. diffusa may be an effective adjuvant to prevent nephrotoxicity induced by the immunosuppressant tacrolimus — but simultaneous modulation of immune pathways and of drug-induced toxicity means herb-drug interactions with tacrolimus and similar agents cannot be excluded.
Diuretic-Related Risks
The diuretic activity of B. diffusa has been attributed to increased sodium excretion rate. This mechanism implies that additive effects with prescription diuretics are pharmacologically plausible. The potential for electrolyte disturbances with excessive use is logically consistent with this mechanism, though systematic human safety data are lacking.
Antifibrinolytic Effects
Root extract of B. diffusa has been found to be effective in reducing stromal edema, inflammation, and tortuosity of glands, and in increasing the degree of deposition of fibrin and platelets in the vessel lumen. This antifibrinolytic activity may represent an interaction risk in individuals taking anticoagulant or antiplatelet medications; however, evidence is from animal/ex vivo models only.
Limitations of Safety Evidence
Further clinical investigations are required to validate efficacy, safety, and standardised formulations. Reports from clinical trials and the specific interaction of isolated phytoconstituents with microbial toxins or molecular markers of pathogenesis are meager.
Roots and leaves represent substantial differences with respect to chemical constituents, and the same plant part collected from different geographical origins may have different metabolite profiles. This variability in phytochemical composition across sources is an important source of uncertainty in both efficacy and safety assessment.
8. Overall Evidence Assessment
Various animal studies and trials have confirmed the presence of pharmacological activities including immunomodulation, hepatoprotection, antifibrinolysis, anticancer activity, antidiabetic activity, anti-inflammation, and diuresis. However, the large majority of this evidence derives from preclinical settings (in vitro cell studies and animal models), and the translation of these findings into confirmed human efficacy has not yet been achieved for most applications.
Modern research on punarnava is still in relatively early stages, with most studies conducted in animals or in laboratory settings rather than large human trials. That said, several areas of investigation show promising results that align with traditional claims.
The pharmacological activities shown by B. diffusa are indicative of the potential of its chemical constituents and their molecular mechanisms. It can be said that B. diffusa is an exceptionally good source of therapeutically active novel phytocompounds which have potential to transform the field of hepatoprotective, nephroprotective, and anticancer treatments.
While its legacy is strong, the scientific evidence remains limited, and its use should be guided by care and context. Rigorous, well-powered, randomized controlled trials in humans are necessary before any definitive therapeutic claims can be made for this plant and its preparations.
References
Go back